Laryngeal Cancer

Clinical Overview

Laryngeal cancer is part of the head and neck squamous cell carcinoma (HNSCC) spectrum, with circulating tumor DNA (ctDNA) demonstrating strong prognostic value for minimal residual disease (MRD) detection and treatment response monitoring. HPV status fundamentally divides these cancers into distinct molecular entities: HPV-positive tumors show PIK3CA alterations with significantly better prognosis (HR 0.28-0.36), while HPV-negative tumors harbor TP53/CDKN2A mutations with worse outcomes. Recent evidence demonstrates that ctDNA positivity after curative-intent treatment confers hazard ratios for recurrence ranging from 5.74 to 27.4 depending on assay type and timing, with detection occurring 3.5-8.4 months before clinical or radiographic progression.

ctDNA Testing Methodology

ctDNA Detection Performance in HNSCC/Laryngeal Cancer

Novel Sampling Approach: Lymphatic Exudate

Recent evidence demonstrates that lymphatic fluid from surgical drains provides superior MRD detection compared to plasma in the immediate postoperative period (Lazare et al. Clinical Cancer Research 2026):

• Lymphatic sample sensitivity: 88% (vs 35% for plasma at early timepoint)
• Lymphatic sample specificity: 67%
• Lead time: 108-253 days (3.5-8.4 months) before clinical progression
• Log-rank p-value: 0.0008 (lymphatic) vs 0.7 (plasma) for early prediction

Prognostic Value of Post-Treatment ctDNA

HPV-Positive Disease: Cell-Free HPV DNA

For HPV-associated laryngeal/oropharyngeal cancer, cell-free HPV DNA (cfHPV-DNA) serves as an excellent tumor biomarker:

• At diagnosis: Sensitivity 81% (95% CI 78-84%), Specificity 98% (95% CI 96-99%)
• During follow-up: Sensitivity 73% (95% CI 57-86%), Specificity 100% (95% CI 99-100%)
• Predictive value: 93% of patients with persistent cfHPV-DNA had occult recurrence
• Multimodal approach: Combined cfHPV-DNA + tumor-informed ctDNA achieved 80% sensitivity and 100% specificity

MRD Detection: Clinical Utility and Outcomes

Prognostic Value After Curative-Intent Treatment

Multimodal MRD Detection Performance

A prospective study compared multiple ctDNA assays at 8-12 weeks post-treatment (Cell Death & Differentiation 2024):

Treatment Response Monitoring

ctDNA dynamics during immunotherapy predict clinical benefit (npj Precision Oncology 2025):

• Population: 16 recurrent/metastatic HNSCC patients receiving immune checkpoint blockade
• Concordance with imaging: 74%
• ctDNA negativity: Strongly associated with disease control
• Rising ctDNA (baseline to first on-treatment): Associated with progressive disease
• Clinical utility: Early kinetics identify 15-20% of patients who benefit from PD-1 inhibitors

Systematic Review: High Negative Predictive Value

A 2026 systematic review (Jones et al. The Laryngoscope) analyzing post-treatment plasma ctDNA monitoring in HNSCC found:

• Negative predictive value: 91.7% for residual/recurrent disease
• Interpretation: Negative ctDNA confers high confidence in disease-free status
• Limitation: Positive predictive value varied between studies; consecutive testing improves PPV

Personalized ctDNA in Surgically Treated HNSCC (npj Precision Oncology 2026)

A recent study demonstrated the utility of personalized, tumor-informed ctDNA analysis for detection of residual disease and recurrence in surgically treated HNSCC patients:

• MRD within 6 weeks of treatment: Associated with worse OS (HR 7.15, 95% CI 1.44-35.34) and RFS (HR 5.39, 95% CI 1.98-21.07)
• Clinical relevance: Early post-treatment ctDNA status independently prognostic for outcomes

Interventional Trial Update: MERIDIAN (NCT05414032)

The MERIDIAN trial is the first interventional study investigating ctDNA-guided MRD interception in HNSCC:

• Design: Phase 2, randomizing MRD-positive patients to bispecific checkpoint inhibitor (AZD2936) vs observation
• Status update: Enrollment paused after 52 patients because only 2 had MRD-positive disease; protocol amended with potentially more sensitive assay and longitudinal sampling (every 3 months)
• Significance: The low MRD detection rate (3.8%) highlights the challenge of ctDNA-guided interception and the need for highly sensitive assays

Genotyping: Clinical Utility for Treatment Selection

Most Common Genomic Alterations in HNSCC

ctDNA sequencing can detect actionable alterations and prognostic biomarkers:

HPV Status as Prognostic and Predictive Biomarker

Multi-Gene Predictive Models

Integrated genomic models improve recurrence risk stratification beyond single-gene analysis:

• 7-gene model: TP53, TERT, IKZF1, EP300, MYC, EGFR, PIK3CA
• Validation AUC: 0.854 for recurrence prediction
• Clinical application: Risk stratification combining genomic and clinical factors
• Advantage: Superior to single-gene analysis alone

Treatment Selection Applications

• PIK3CA mutations: Enrollment in PI3K/mTOR inhibitor trials (alpelisib, everolimus)
• EGFR amplifications: Consideration of afatinib (exploratory use based on HNSCC subset analyses)
• High tumor mutation burden: May predict immunotherapy benefit (correlation with PD-L1 expression)
• TP53 mutations: Prognostic information; component of predictive algorithms

Clinical Summary

Bottom Line: Laryngeal cancer (as part of the HNSCC spectrum) shows strong Level 2 evidence for ctDNA-based MRD detection as a prognostic biomarker, with hazard ratios exceeding 7 in most studies and lead times of 3.5-8.4 months before imaging. HPV status determines optimal ctDNA approach: cfHPV-DNA for HPV-positive disease, tumor-informed somatic ctDNA for HPV-negative disease. While prognostic utility is established, prospective trials are needed before ctDNA-guided treatment modifications become standard of care. Current applications include risk stratification, surveillance augmentation, and clinical trial eligibility determination.